Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement

Annals of Internal Medicine

Volumn 164, Issue 12, 2016, Pages 836-845

  Bibbins Domingo, Kirsten ^a,b   Grossman, David C ^c   Curry, Susan J ^d   Davidson, Karina W ^e   Epling, John W ^f   García, Francisco A R ^g   Gillman, Matthew ^h   Harper, Diane M ⁱ   Kemper, Alex R ^j   Krist, Alex H ^k,l   Kurth, Ann E ^m   Landefeld, C Seth ⁿ   Mangione, Carol M ^o   Phillips, William R ^p   Phipps, Maureen G ^q   Pignone, Michael P ^r   Siu, Albert L ^s   Owens, Douglas K ^s   LeFevre, Michael L ^s  

^a US Preventive Services Task Force   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^g Pima County Health Department   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF LOUISVILLE   (United States)

^j DUKE UNIVERSITY   (United States)

^k Fairfax Family Practice Centers   (United States)

^l VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^m YALE UNIVERSITY SCHOOL OF NURSING   (United States)

ⁿ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF WASHINGTON   (United States)

^q BROWN UNIVERSITY   (United States)

^r UNIVERSITY OF NORTH CAROLINA   (United States)

^s NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; FIBRINOLYTIC AGENT;

ADULT; AGED; BLEEDING; BRAIN HEMORRHAGE; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COLORECTAL CANCER; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HUMAN; LIFE EXPECTANCY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT DURATION; TREATMENT INDICATION; UNITED STATES; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; PRACTICE GUIDELINE; RISK ASSESSMENT;

ADULT; ANTICARCINOGENIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PRIMARY PREVENTION; RISK ASSESSMENT;

EID: 84975292439     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-0577     Document Type: Review

References (38)

1. Heron M. Deaths: leading causes for 2011. Natl Vital Stat Rep. 2015;64:1-96. [PMID: 26222685]
2. Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 131. AHRQ Publication No. 13-05195-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
3. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935-59. [PMID: 24239921] doi: 10.1016/j.jacc.2013.11.005
4. Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms. A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 132. AHRQ Publication No. 13-05193-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
5. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:826-35. doi: 10.7326/M15-2112
6. Chubak J, Kamineni A, Buist DSM, Anderson ML, Whitlock EP. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 133. AHRQ Publication No. 15-05228- EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
7. Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DSM, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:814-25. doi: 10.7326/M15-2117
8. Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP. Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:777-86. doi: 10.7326/M15-2129
9. Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22. [PMID: 16987411]
10. De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286-94. [PMID: 22706834] doi: 10.1001/jama.2012.5034
11. Walker J, Robinson J, Stewart J, Jacob S. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interact Cardiovasc Thorac Surg. 2007; 6:519-22. [PMID: 17669925]
12. Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: A Decision Analysis. AHRQ Publication No. 15-05229-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
13. Mainous AG, Tanner RJ, Shorr RI, Limacher MC. Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012. J Am Heart Assoc. 2014;3. [PMID: 25023071] doi: 10.1161/JAHA.114.000989
14. Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:804-13. doi: 10.7326/M15-2113
15. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-41. [PMID: 18997198] doi: 10.1001/jama.2008.623
16. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al; Prevention of Progression of Arterial Disease and Diabetes Study Group. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. [PMID: 18927173] doi: 10.1136/bmj.a1840
17. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841-8. [PMID: 20197530] doi: 10.1001/jama.2010.221
18. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-35. [PMID: 2664509]
19. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet. 1998;351:233-41. [PMID: 9457092]
20. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA. 1992;268:1292-300. [PMID: 1507375]
21. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. [PMID: 9635947]
22. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296:313-6. [PMID:3125882]
23. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352:1293-304. [PMID: 15753114]
24. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89-95. [PMID: 11197445]
25. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312: 2510-20. [PMID: 25401325] doi: 10.1001/jama.2014.15690
26. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-54. [PMID: 1783914]
27. Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603-13. [PMID: 17499602]
28. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternateday, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77-85. [PMID: 23856681] doi: 10.7326/0003-4819-159-2-201307160-00002
29. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741-50. [PMID: 20970847] doi: 10.1016/S0140-6736(10)61543-7
30. Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Alonso- Abreu I, Perez-Aisa MA, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104:1633-41. [PMID: 19574968] doi: 10.1038/ajg.2009.164
31. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. [PMID: 19482214] doi: 10.1016/S0140-6736(09)60503-1
32. Nemerovski CW, Salinitri FD, Morbitzer KA, Moser LR. Aspirin for primary prevention of cardiovascular disease events. Pharmacotherapy. 2012;32:1020-35. [PMID: 23019080] doi: 10.1002/phar.1127
33. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev. 2008;88: 1547-65. [PMID: 18923189] doi: 10.1152/physrev.00004.2008
34. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al; American Heart Association Stroke Council. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:517-84. [PMID: 21127304]doi: 10.1161/STR.0b013e3181fcb238
35. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al; American Diabetes Association. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010;33:1395-402. [PMID: 20508233] doi: 10.2337/dc10-0555
36. American Academy of Family Physicians. Clinical Preventive Service Recommendation: Cardiovascular Disease. 2009. Accessed at www.aafp.org/patient-care/clinical-recommendations/all/cvd.html on 14 March 2016.
37. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al; American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e637S-68S. [PMID: 22315274] doi: 10.1378/chest.11-2306
38. U.S. Food and Drug Administration. Citizen Petition Denial Response From FDA to Bayer Healthcare LLC. Docket ID: FDA-1977-N-0018. 2014. Accessed at www.regulations.gov/#!documentDetail; D=FDA-1977-N-0018-0101 on 14 March 2016.